RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") announced today that the Company has received an issued patent in Mexico and allowances of three additional patent applications in Mexico and Israel. The issued Mexican patent relates to uses of Tβ4 to treat or prevent biological or immunological responses to reactive chemical or biological agents, or toxins. Three separate applications in Mexico also have received notification of allowance. These patents will cover uses of Tβ4 for elevated intraocular pressure and dry eye, congestive heart failure, and damage resulting from increases in blood flow, such as reperfusion injury, associated with opening blocked arteries. The Israeli patent will cover uses of Thymosin beta 4 (Tβ4) and Tβ4 fragments for use in various neuromuscular conditions. The patents are set to expire 2024-2026.